Shandong Xinhua Pharmaceutical Company Limitedの最新の1株当たり利益は$で、$0.11の予想を。
Shandong Xinhua Pharmaceutical Company Limited SHNXYの前四半期の収益はどうでしたか?
Shandong Xinhua Pharmaceutical Company Limitedの前四半期の収益は$です。
Shandong Xinhua Pharmaceutical Company Limitedの収益見積もりはいくらですか?
人のウォール街のアナリストによると、Shandong Xinhua Pharmaceutical Company Limitedの収益見積もりは$から$の範囲です。
Shandong Xinhua Pharmaceutical Company Limitedの収益品質スコアはどれくらいですか?
Shandong Xinhua Pharmaceutical Company Limitedの収益品質スコアは/です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
Shandong Xinhua Pharmaceutical Company Limitedはいつ収益を報告しますか?
Shandong Xinhua Pharmaceutical Company Limitedの次の収益報告は2026-01-23に予定されています
Shandong Xinhua Pharmaceutical Company Limitedの予想収益はいくらですか?
ウォール街のアナリストによると、Shandong Xinhua Pharmaceutical Company Limitedの予想収益は$です。
Shandong Xinhua Pharmaceutical Company Limitedは収益予想を上回りましたか?
Shandong Xinhua Pharmaceutical Company Limitedの最近の収益は$で、予想を。
主要データ
前終値
$18.19
始値
$18.19
当日レンジ
$18.19 - $18.19
52週レンジ
$18.19 - $18.19
取引高
100
平均取引高
0
配当利回り
--
1株当たり利益(TTM)
0.80
時価総額
$899.9M
SHANDONG XINHUA PHARMACEUTICAL とは何ですか?
Shandong Xinhua Pharmaceutical Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Zibo, Shandong and currently employs 7,296 full-time employees. Shandong Xinhua Pharmaceutical Co Ltd is a China-based company mainly engaged in the development, manufacturing and sales of chemical raw materials, pharmaceutical preparations and chemical products. The firm operates three segments. The Chemical Raw Materials segment is mainly engaged in the development, manufacturing and sales of raw materials for antipyretics and analgesics such as caffeine series, ibuprofen series, aspirin series, dopamine series, barbiturates and pipemidic acid. The Pharmaceutical Preparations segment is mainly engaged in the development, manufacturing and sales of tablets, injections and capsules such as pipemidic acid tablets, aminopyrine and nimodipine tablets. The Pharmaceutical Intermediates and Other Products segment is mainly engaged in the development, manufacturing and sales of pharmaceutical intermediates and other products. The firm mainly operates its business in the domestic market and overseas markets such as the Americas and Europe.